Episode
Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)
- Published
- Mar 11, 2026
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial. Content: - What is the role of autologous stem cell transplant in the management of multiple myeloma? - How did we get to our current standards of care? - How is minimal residual disease (MRD) fitting into our treatment paradigm? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube